Navigation Links
Leading Pharma Company Selects Clinilabs to Conduct a Phase 1 Study of an Investigational Type 2 Diabetes Medication
Date:9/30/2013

NEW YORK, Sept. 30, 2013 /PRNewswire-iReach/ -- Clinilabs, a contract research organization that provides early-stage and specialty clinical drug development services to industry, announced today that they have begun a Phase I clinical research study of an investigational medication for Type 2 Diabetes Mellitus.  The study is being conducted to assess the safety and tolerability of multiple daily doses of the investigational medication over periods of up to 28 days.  

Diabetes has become one of the most prevalent diseases in the United States, with approximately 2 million people diagnosed each year.  The Center for Disease Control and Prevention estimates that roughly 35% of the population over the age of 20 is pre-diabetic.  For those over the age of 65, this number increases to 50%.  Clinilabs understands the growing need for treatment options in this field and is dedicated to helping sufferers combat the disease.  In response to the study award, Lead Recruiter Carrie Sorkin states: "Patients understand that clinical trials are a great way to find alternative treatment options for diabetes.  At Clinilabs, we have seen this first-hand through the great success we have had in our recruitment efforts."

Clinilabs is currently enrolling male and female volunteers, between the ages of 18 and 70, who have been diagnosed with Type 2 Diabetes Mellitus.  Any female patients interested in volunteering for this study must not be of childbearing potential. Patients must be on a stable treatment regimen for at least 4 weeks prior to screening and must have a body weight of above 45.0 kg.

Individuals in the Central New Jersey area who would like to participate can contact our dedicated call center at 212-994-4567 to prequalify.  Additional information may also be found by visiting www.clinilabs.com/volunteers.  If you are a Physician in the New Jersey or New York area and are interested in referring patients for this trial please contact us at info@clinilabs.com.

About Clinilabs Inc.

Clinilabs is a full-service contract research organization (CRO) that specializes in early-phase studies, from first-in-human to proof-of-concept, with normal healthy volunteers and patient populations.  The company owns and operates two Phase I units in the US, and maintains a network of highly qualified investigator sites for multicenter Phase II studies Worldwide.  Specialty projects, including pharmacodynamic, biomarker, cardiac safety, sleep/wakefulness, metabolic, and Japanese bridging are among our strengths.  Clinilabs is recognized globally as a leading specialty CRO, offering an alternative to large CROs for specialty projects.  For more information, please visit www.clinilabs.com.

Media Contact: Hannah DAoust, Clinilabs, 646-215-6480, hdaoust@clinilabs.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Clinilabs
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Leading evolutionary scientist to discuss how genome of bacteria has evolved
2. Worlds leading coral experts to gather in Australia
3. Putting plants online: 4 leading botanical gardens to create first online catalog of all plants
4. EMBO welcomes 55 leading life scientists as members
5. Leading statistician receives national citation award
6. Leading childhood asthma group supports federal asthma action plan to reduce disparities
7. BiOptix Participates in Leading Life Sciences Event BioWest 2012
8. Team including UC Riverside entomologist honored for research leading to healthier potato chips
9. Aware Enables Automated Delivery of Radiation Dose Information Through Integration With Leading Radiology Reporting System
10. Discovery of pathway leading to depression reveals new drug targets
11. Leading RSV researcher publishes work at Le Bonheur Childrens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/27/2016)... , Jan. 27, 2016  Rite Track, Inc. ... in West Chester, Ohio announced ... winning service staff, based in Austin, Texas ... and ability to provide modifications, installations and technical support ... , CEO of PLUS, commented, "PLUS has provided world ...
(Date:1/22/2016)... 2016 http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ... the  "Global Behavioral Biometric Market 2016-2020" ... http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the ... Market 2016-2020"  report to their offering. ... http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the addition ...
(Date:1/20/2016)... Jan. 20, 2016 A market that just ... benefit from the explosion in genomics knowledge. Learn all ... Research. A range of dynamic trends are pushing market ... personalized medicine - pharmacogenomics - pathogen evolution - next ... markets - greater understanding of the role of genetic ...
Breaking Biology News(10 mins):
(Date:2/8/2016)... 8, 2016  NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), a ... Seymour , MD, MPH, will present information about the company,s programs ... in New York City . ... Windsor Room at 5:30PM EST. Registered attendees can request a one ... City . --> New York City ...
(Date:2/6/2016)... McLean, VA (PRWEB) , ... February 06, 2016 , ... ... enrichment session, cost-free, for middle and high school teachers on Wednesday February 10, 2016. ... be held at the Smithsonian-Mason School of Conservation, located at 1500 Remount Road in ...
(Date:2/5/2016)... DIEGO , Feb. 5, 2016 On ... region,s trusted information source for community, health and disaster ... Diego) will integrate to enhance care coordination and ... to the services they need and to better connect ... improve care.   San Diego ...
(Date:2/4/2016)... - New FDA action date of July ... action date of July 22, 2016   --> ... 22, 2016   - Lifitegrast has the ... for the treatment of signs and symptoms of dry eye disease ... to be the only product approved in the U.S. in the past decade indicated for ...
Breaking Biology Technology: